Assessment of Digital Breast Tomosynthesis (DBT) in the Screening Environment
Completed · Not applicable
Conditions studied: Breast Abnormalities
In brief
The objective of this study is to demonstrate that digital breast tomosynthesis (DBT) in combination with full field digital mammography (FFDM) has the potential to reduce significantly baseline screening recall rates without a loss in the detection of cancers. The primary hypothesis of the study is that DBT in combination with FFDM will reduce baseline screening mammography recall rates in negative examinations by at least 20%.
Key facts
- Study ID
- NCT01106911
- Run by
- University of Pittsburgh
- People needed
- 1080
- Starts
- 2010-05-01
- Last updated by the study team
- 2016-03-25
Who can join
Age: 35 and older, up to 55. Sex: female. Healthy volunteers: accepted.
You may qualify if…
- Women between the ages of 34 and 56.
- Women presenting for their baseline screening mammography examination
You may not qualify if…
- Women with a palpable finding(s) via a Breast Self Examination (BSE) or Clinical Breast Examination (CBE).
- Women who may be or are pregnant by self report
- Women older than 55 years of age or younger than 35.
- Women with known fatty breast tissue
- Males and children
- Women who are unable to understand or execute written informed consent
Where it is running
- Magee-Womens Hospital — Pittsburgh, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.